NewEdge Advisors LLC Boosts Stock Position in GSK PLC Sponsored ADR $GSK

NewEdge Advisors LLC grew its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 8.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 90,663 shares of the pharmaceutical company’s stock after buying an additional 7,148 shares during the period. NewEdge Advisors LLC’s holdings in GSK were worth $3,512,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Dodge & Cox increased its holdings in shares of GSK by 14.9% in the 1st quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company’s stock valued at $3,046,972,000 after acquiring an additional 10,210,921 shares during the last quarter. Primecap Management Co. CA increased its stake in GSK by 1.8% in the first quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company’s stock valued at $995,929,000 after purchasing an additional 446,360 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in GSK by 2.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,722,314 shares of the pharmaceutical company’s stock valued at $299,163,000 after purchasing an additional 155,392 shares during the last quarter. Royal Bank of Canada raised its holdings in GSK by 5.7% during the first quarter. Royal Bank of Canada now owns 7,581,079 shares of the pharmaceutical company’s stock worth $293,692,000 after purchasing an additional 411,869 shares in the last quarter. Finally, Equity Investment Corp lifted its position in shares of GSK by 5.3% during the 1st quarter. Equity Investment Corp now owns 4,174,189 shares of the pharmaceutical company’s stock worth $161,708,000 after buying an additional 211,608 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Trading Up 2.1%

NYSE GSK opened at $40.88 on Wednesday. The firm’s fifty day moving average is $38.59 and its two-hundred day moving average is $38.40. GSK PLC Sponsored ADR has a one year low of $31.72 and a one year high of $44.19. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. The firm has a market cap of $83.26 billion, a PE ratio of 18.93, a P/E/G ratio of 2.00 and a beta of 0.53.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.11. The firm had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business’s revenue was up 1.3% on a year-over-year basis. During the same quarter last year, the company posted $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be paid a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a dividend yield of 4.1%. The ex-dividend date is Friday, August 15th. GSK’s dividend payout ratio is 77.78%.

Wall Street Analyst Weigh In

A number of research firms recently commented on GSK. Wall Street Zen raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. Berenberg Bank reaffirmed a “hold” rating on shares of GSK in a report on Tuesday, June 3rd. Six research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, GSK has an average rating of “Reduce” and an average price target of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.